EMA perspective: Cmax less than 5% for Test Product [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2013-08-20 16:21 (4691 d 08:05 ago) – Posting: # 11321
Views: 2,820

Dear all
A BCS class I substance is characterized by very good solubility and very high bioavailability. So if you have no plasma concentrations you can be pretty shure that the subject did not take the drug. In this case I think it could be possible to argue with the regulatory authority and maybe your assessor is willing to follow your argumentation. It is a chance.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
126 visitors (0 registered, 126 guests [including 34 identified bots]).
Forum time: 00:26 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5